Spots Global Cancer Trial Database for sorafenib
Every month we try and update this database with for sorafenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01170104 | Hepatocellular ... | Sorafenib TACE (Transcath... | 18 Years - | Chung-Ang University | |
| Depocyt® With Sorafenib in Neoplastic Meningitis | NCT00964743 | Neoplastic Meni... | DepoCyt Sorafenib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Metastatic Advanced Pancreas Sorafenib | NCT00758381 | Locally Advance... | Sorafenib 400 m... Gemcitabina, Ci... | 18 Years - 75 Years | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | |
| Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment | NCT00839111 | Colorectal Neop... | sorafenib FOLFIRI | 18 Years - 75 Years | Fudan University | |
| A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | NCT02423239 | Hepatocellular ... Pancreatic Canc... | Dexanabinol Sorafenib Nab-paclitaxel Gemcitabine | 18 Years - | e-Therapeutics PLC | |
| Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | NCT03812770 | Hepatocellular ... | Sorafenib HAIC of FOLFOX HAIC of OXA | 18 Years - 75 Years | Sun Yat-sen University | |
| Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01135056 | Hepatocellular ... | SIR-Spheres Sorafenib tosyl... | 18 Years - | Singapore General Hospital | |
| Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT00714948 | Bladder Cancer URINARY BLADDER | gemcitabine and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients | NCT02330783 | Metastatic Rena... | Bevacizumab Sorafenib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | NCT04992143 | BCLC Stage C He... | TACE Tilelizumab Sorafenib | 18 Years - | First Affiliated Hospital of Zhejiang University | |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | NCT02298348 | Neuroblastoma | Sorafenib Cyclophosphamid... Topotecan | - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer | NCT01025453 | Thyroid Cancer | Temsirolimus an... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Combined Radiotherapy and Sorafenib in Patients With Hepatoma | NCT01319942 | Hepatocellular ... | Radiotherapy co... | 20 Years - 69 Years | China Medical University Hospital | |
| Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria | NCT01141478 | Carcinoma, Hepa... | Proton Beam Rad... Sorafenib | 18 Years - 80 Years | Loma Linda University | |
| Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | NCT01730937 | Adult Primary H... Advanced Adult ... Recurrent Adult... | Sorafenib stereotactic bo... | 18 Years - | Radiation Therapy Oncology Group | |
| Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies | NCT00449280 | Advanced Solid ... | Sorafenib Rapamycin Rapamycin | 18 Years - | University of Chicago | |
| Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | NCT00576056 | Carcinoma, Hepa... | Sorafenib TACE | 18 Years - 100 Years | University of Pittsburgh | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | NCT01189370 | Renal Cell Canc... | sorafenib | 18 Years - | University of Kansas Medical Center | |
| Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer | NCT00694291 | Prostate Cancer | Sorafenib Placebo | 18 Years - | Fox Chase Cancer Center | |
| Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy | NCT01539681 | Hepatocellular ... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) | NCT01230697 | Kidney Cancer Liver Cancer | Sorafenib | 18 Years - | University of Turin, Italy | |
| Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma | NCT01903694 | Child-Pugh A He... | Sorafenib + Pra... Sorafenib | 18 Years - | Centre Hospitalier Universitaire Dijon | |
| Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection | NCT02537158 | Hepatocellular ... | Sorafenib TACE | 18 Years - 75 Years | ChineseAMS | |
| A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis | NCT03178656 | Portal Vein Tum... | Sorafenib surgery | 20 Years - 75 Years | Huazhong University of Science and Technology | |
| A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma | NCT01171651 | Carcinoma, Hepa... | JX-594 followed... | 18 Years - | SillaJen, Inc. | |
| Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | NCT02474290 | Acute Myeloid L... Hematopoietic S... | Sorafenib | 18 Years - 60 Years | Nanfang Hospital, Southern Medical University | |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | NCT00597493 | Recurrent Gliob... | Sorafenib and T... | 18 Years - | Duke University | |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| Sorafenib/Docetaxel Dose Escalation Trial | NCT00562523 | Neoplasms | Sorafenib (Nexa... | 18 Years - | Bayer | |
| Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO) | NCT00661830 | Adenocarcinoma | Gemcitabine Placebo Sorafenib | 18 Years - | Johannes Gutenberg University Mainz | |
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | NCT00542971 | AML Acute Myeloid L... Myelodysplastic... | Idarubicin Sorafenib Ara-C | 15 Years - 60 Years | M.D. Anderson Cancer Center | |
| Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma | NCT04926532 | Hepatocellular ... | Toripalimab Sorafenib | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients | NCT02642913 | Hepatocellular ... | Enzalutamide Enzalutamide wi... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | NCT00436215 | Ovarian Neoplas... Fallopian Tube ... Primary Periton... | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Depocyt® With Sorafenib in Neoplastic Meningitis | NCT00964743 | Neoplastic Meni... | DepoCyt Sorafenib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC | NCT01214343 | Advanced Hepato... Carcinoma Carcinoma, Hepa... Liver Neoplasms Neoplasms | Sorafenib with ... Sorafenib | 20 Years - | Ministry of Health, Labour and Welfare, Japan | |
| Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | NCT00943943 | Acute Myelogeno... Leukemia | G-CSF Plerixafor Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT00714948 | Bladder Cancer URINARY BLADDER | gemcitabine and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas | NCT00217620 | Sarcoma | sorafenib | 18 Years - | National Cancer Institute (NCI) | |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | NCT05717738 | Hepatocellular ... | TACE Lenvatinib Anti-PD-1 monoc... Bevacizumab Bio... Bevacizumab plu... apatinib plus c... Sorafenib Donafenib Regorafenib | 18 Years - | Tongji Hospital | |
| Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting | NCT01557127 | Carcinoma, Rena... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | NCT03794440 | Hepatocellular ... | Sintilimab IBI305 Sorafenib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01170104 | Hepatocellular ... | Sorafenib TACE (Transcath... | 18 Years - | Chung-Ang University | |
| Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors | NCT00572078 | SOLID TUMORS | Sorafenib | 18 Years - | Indiana University | |
| An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | NCT01076010 | Advanced Renal ... | Tivozanib Sorafenib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | NCT00692770 | Carcinoma, Hepa... | Nexavar (Sorafe... Placebo | 18 Years - | Bayer | |
| Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer | NCT00619996 | Prostate Cancer | Sorafenib (Nexa... Docetaxel | - | Italian Trial in Medical Oncology | |
| Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma | NCT01736878 | Medullary Thyro... | Sorafenib | 18 Years - | Eanm Research Ltd | |
| Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC | NCT04723004 | Advanced Hepato... | Toripalimab com... Sorafenib | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors | NCT02450149 | Refractory Soli... | sorafenib | 20 Years - | Samsung Medical Center | |
| Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan | NCT02776644 | Renal Cell Carc... | - | Pfizer | ||
| Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | NCT03412773 | Hepatocellular ... | Tislelizumab Sorafenib | 18 Years - | BeiGene | |
| Immunotherapy for Advanced Liver Cancer | NCT05033522 | Hepatocellular ... | AlloStim® immun... FOLFOX regimen Sorafenib Lenvatinib | 18 Years - 80 Years | Immunovative Therapies, Ltd. | |
| A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | NCT04039607 | Hepatocellular ... | Nivolumab Ipilimumab Sorafenib lenvatinib | 18 Years - | Bristol-Myers Squibb | |
| Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | NCT03037437 | Hepatocellular ... | Sorafenib (SOR) Hydroxychloroqu... | 18 Years - 100 Years | The University of Texas Health Science Center at San Antonio | |
| A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) | NCT02627963 | Carcinoma, Rena... | Tivozanib hydro... Sorafenib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma | NCT02425605 | Hepatocellular ... | CCRT sorafenib | 20 Years - 75 Years | Yonsei University | |
| Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | NCT00791544 | Liver Carcinoma | AVE1642 sorafenib erlotinib | 18 Years - | Sanofi | |
| AflacLL1901 (CHOA-AML) | NCT04326439 | Acute Myeloid L... AML, Childhood | Cytarabine Daunorubicin Erwinase Etoposide Gemtuzumab ozog... Stem cell trans... Sorafenib | - 21 Years | Emory University | |
| Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | NCT00727532 | Hereditary Clea... Kidney Cancer | Sorafenib | 18 Years - 120 Years | Northwestern University | |
| Sorafenib + mFOLFOX for Hepatocellular Carcinoma | NCT01775501 | Hepatocellular ... | Leucovorin Fluorouracil Oxaliplatin Sorafenib | 18 Years - | Massachusetts General Hospital | |
| Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma | NCT04553458 | Hepatocellular ... | Radiofrequency ... Trance-arterial... Liver resection Combined radiof... Percutaneous et... Systemic chemot... Sorafenib Viscum Symptomatic tre... | 18 Years - | Sohag University | |
| Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) | NCT04170556 | Hepatocellular ... | Regorafenib Nivolumab | 18 Years - | Fundacion Clinic per a la Recerca Biomédica | |
| Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer | NCT04163237 | Advanced Liver ... | PD-1 Sorafenib | - | Guangxi Medical University | |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma | NCT00498836 | Malignant Melan... | CP-4055 Sorafenib (Nexa... | 18 Years - | Clavis Pharma | |
| Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | NCT01272557 | Liver Carcinoma | Doxorubicin Sorafenib | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| A Study of Radiation With Sorafenib in Advanced Cancer | NCT00610246 | Cancer | Sorafenib | 18 Years - | University Health Network, Toronto | |
| Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer | NCT00417248 | Non-Small Cell ... | Cisplatin Etoposide Radiotherapy Sorafenib | 18 Years - | Hoosier Cancer Research Network | |
| Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone | NCT01263951 | Differentiated ... | Everolimus Sorafenib | 18 Years - 89 Years | Thomas Jefferson University | |
| Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma | NCT01932385 | Liver Cancer | Sorafenib Best Supportive... | 18 Years - 80 Years | Qingdao Central Hospital | |
| Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study | NCT05117957 | Advanced Hepato... | Sorafenib | 20 Years - | National Cancer Center, Korea | |
| Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies | NCT02270788 | Acute Myeloid L... | Crenolanib Sorafenib methotrexate, h... | 1 Year - 39 Years | St. Jude Children's Research Hospital | |
| Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma | NCT00541840 | Soft Tissue Sar... | Sorafenib | 18 Years - 72 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01170104 | Hepatocellular ... | Sorafenib TACE (Transcath... | 18 Years - | Chung-Ang University | |
| Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC | NCT00801801 | Non Squamous Ce... Non Small Cell ... | Docetaxel + Sor... | 19 Years - | University of Alabama at Birmingham | |
| Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib | NCT01246843 | Metastatic Rena... GIST | 18 Years - | Radboud University Medical Center | ||
| Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | NCT00791544 | Liver Carcinoma | AVE1642 sorafenib erlotinib | 18 Years - | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
